Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Myelofibrosis patients can develop extramedullary complications including renal amyloidosis and sclerosing hematopoietic tumor while otherwise meeting traditional measures of ruxolitinib response.

Literature DB >> 30227762

Myelofibrosis patients can develop extramedullary complications including renal amyloidosis and sclerosing hematopoietic tumor while otherwise meeting traditional measures of ruxolitinib response.

Daria V Babushok^1,2, Ernest J Nelson³, Jennifer J D Morrissette³, Shivam Joshi⁴, Matthew B Palmer³, Dale Frank³, Carolyn L Cambor³, Elizabeth O Hexner¹.

Abstract

Entities: Chemical Disease Gene Mutation Species

Mesh：

Substances：

Year: 2018 PMID： 30227762 PMCID： PMC6424649 DOI： 10.1080/10428194.2018.1509319

Source DB: PubMed Journal: Leuk Lymphoma ISSN： 1026-8022

× No keyword cloud information.

14 in total

1. Sclerosing extramedullary hematopoietic tumor involving lesser omentum and ligamentumteres in liver explant.

Authors: Youngmee Kwon; Eunsil Yu; Jooryung Huh; Seung Kyu Lee; Jae Y Ro
Journal: Ann Diagn Pathol Date: 2004-08 Impact factor: 2.090

2. Sclerosing extramedullary hematopoietic tumor in chronic myeloproliferative disorders.

Authors: E D Remstein; P J Kurtin; A G Nascimento
Journal: Am J Surg Pathol Date: 2000-01 Impact factor: 6.394

3. Secondary amyloidosis in the course of idiopathic myelofibrosis.

Authors: B Ferhanoğlu; Y Erzin; Z Başlar; H A Tüzüner
Journal: Leuk Res Date: 1997-09 Impact factor: 3.156

4. Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?

Authors: Elsa Lestang; Pierre Peterlin; Yannick Le Bris; Viviane Dubruille; Jacques Delaunay; Catherine Godon; Olivier Theisen; Nicolas Blin; Beatrice Mahe; Thomas Gastinne; Alice Garnier; Cyrille Touzeau; Maud Voldoire; Marie C Bene; Steven Le Gouill; Noel Milpied; Mohamad Mohty; Philippe Moreau; Thierry Guillaume; Patrice Chevallier
Journal: Eur J Haematol Date: 2017-05-05 Impact factor: 2.997

5. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

Authors: Srdan Verstovsek; Ruben A Mesa; Jason Gotlib; Richard S Levy; Vikas Gupta; John F DiPersio; John V Catalano; Michael Deininger; Carole Miller; Richard T Silver; Moshe Talpaz; Elliott F Winton; Jimmie H Harvey; Murat O Arcasoy; Elizabeth Hexner; Roger M Lyons; Ronald Paquette; Azra Raza; Kris Vaddi; Susan Erickson-Viitanen; Iphigenia L Koumenis; William Sun; Victor Sandor; Hagop M Kantarjian
Journal: N Engl J Med Date: 2012-03-01 Impact factor: 91.245

6. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Authors: Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi
Journal: N Engl J Med Date: 2012-03-01 Impact factor: 91.245

10. Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis.

Authors: Hans Michael Kvasnicka; Jürgen Thiele; Carlos E Bueso-Ramos; William Sun; Jorge Cortes; Hagop M Kantarjian; Srdan Verstovsek
Journal: J Hematol Oncol Date: 2018-03-15 Impact factor: 17.388

1 in total

1. [Primary intraosseous hematopoietic pseudotumor: clinicopathological analysis and 9-year follow-up of 3 cases].

Authors: Na Tang; Suqi Deng; Yongjian Deng
Journal: Nan Fang Yi Ke Da Xue Xue Bao Date: 2019-08-30